vs

Side-by-side financial comparison of INNOVATIVE INDUSTRIAL PROPERTIES INC (IIPR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $66.7M, roughly 1.1× INNOVATIVE INDUSTRIAL PROPERTIES INC). INNOVATIVE INDUSTRIAL PROPERTIES INC runs the higher net margin — 47.8% vs -49.0%, a 96.8% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -13.1%).

Oxford Properties is a Canadian multinational corporation, with operations in real estate investment, development and property management. Its portfolio includes office, retail, industrial, multi-residential, life sciences and hotel assets. Established privately in 1960 and later wholly owned by the Ontario Municipal Employees Retirement System (OMERS) since 2003, the company is headquartered in Toronto with regional head offices in New York City, London, Australia, Singapore and Luxembourg. ...

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

IIPR vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.1× larger
VRDN
$70.6M
$66.7M
IIPR
Growing faster (revenue YoY)
VRDN
VRDN
+81971.3% gap
VRDN
81958.1%
-13.1%
IIPR
Higher net margin
IIPR
IIPR
96.8% more per $
IIPR
47.8%
-49.0%
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IIPR
IIPR
VRDN
VRDN
Revenue
$66.7M
$70.6M
Net Profit
$31.8M
$-34.6M
Gross Margin
Operating Margin
47.8%
-56.7%
Net Margin
47.8%
-49.0%
Revenue YoY
-13.1%
81958.1%
Net Profit YoY
-20.4%
54.9%
EPS (diluted)
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IIPR
IIPR
VRDN
VRDN
Q4 25
$66.7M
Q3 25
$64.7M
$70.6M
Q2 25
$62.9M
Q1 25
$71.7M
Q4 24
$76.7M
Q3 24
$76.5M
Q2 24
$79.8M
Q1 24
$75.5M
Net Profit
IIPR
IIPR
VRDN
VRDN
Q4 25
$31.8M
Q3 25
$29.3M
$-34.6M
Q2 25
$26.0M
Q1 25
$31.1M
Q4 24
$40.0M
Q3 24
$40.2M
Q2 24
$42.0M
Q1 24
$39.4M
Operating Margin
IIPR
IIPR
VRDN
VRDN
Q4 25
47.8%
Q3 25
45.5%
-56.7%
Q2 25
45.9%
Q1 25
47.4%
Q4 24
54.7%
Q3 24
54.8%
Q2 24
53.1%
Q1 24
55.7%
Net Margin
IIPR
IIPR
VRDN
VRDN
Q4 25
47.8%
Q3 25
45.3%
-49.0%
Q2 25
41.4%
Q1 25
43.3%
Q4 24
52.2%
Q3 24
52.6%
Q2 24
52.6%
Q1 24
52.3%
EPS (diluted)
IIPR
IIPR
VRDN
VRDN
Q4 25
$1.07
Q3 25
$0.97
Q2 25
$0.86
Q1 25
$1.03
Q4 24
$1.35
Q3 24
$1.37
Q2 24
$1.44
Q1 24
$1.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IIPR
IIPR
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$47.6M
$490.9M
Total DebtLower is stronger
$393.7M
Stockholders' EquityBook value
$1.8B
$503.0M
Total Assets
$2.4B
$577.1M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IIPR
IIPR
VRDN
VRDN
Q4 25
$47.6M
Q3 25
$41.9M
$490.9M
Q2 25
$104.9M
Q1 25
$133.3M
Q4 24
$151.2M
Q3 24
$172.4M
Q2 24
$160.9M
Q1 24
$173.5M
Total Debt
IIPR
IIPR
VRDN
VRDN
Q4 25
$393.7M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IIPR
IIPR
VRDN
VRDN
Q4 25
$1.8B
Q3 25
$1.9B
$503.0M
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$1.9B
Q3 24
$1.9B
Q2 24
$1.9B
Q1 24
$2.0B
Total Assets
IIPR
IIPR
VRDN
VRDN
Q4 25
$2.4B
Q3 25
$2.3B
$577.1M
Q2 25
$2.3B
Q1 25
$2.4B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Q1 24
$2.4B
Debt / Equity
IIPR
IIPR
VRDN
VRDN
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IIPR
IIPR
VRDN
VRDN
Operating Cash FlowLast quarter
$198.2M
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
6.22×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IIPR
IIPR
VRDN
VRDN
Q4 25
$198.2M
Q3 25
$45.6M
$-84.6M
Q2 25
$48.4M
Q1 25
$54.2M
Q4 24
$258.4M
Q3 24
$64.9M
Q2 24
$64.2M
Q1 24
$71.6M
Free Cash Flow
IIPR
IIPR
VRDN
VRDN
Q4 25
Q3 25
$-84.7M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
IIPR
IIPR
VRDN
VRDN
Q4 25
Q3 25
-120.1%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
IIPR
IIPR
VRDN
VRDN
Q4 25
Q3 25
0.2%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
IIPR
IIPR
VRDN
VRDN
Q4 25
6.22×
Q3 25
1.56×
Q2 25
1.86×
Q1 25
1.75×
Q4 24
6.46×
Q3 24
1.61×
Q2 24
1.53×
Q1 24
1.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons